Anti-TIKI1/ TRABD2A/ C2orf89 functional antibody

Anti-TIKI1/ TRABD2A/ C2orf89 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to TRABD2A/TRABD2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0525-Ab-1/ GM-Tg-hg-SE0525-Ab-2Anti-Human TRABD2A monoclonal antibodyHuman
GM-Tg-rg-SE0525-Ab-1/ GM-Tg-rg-SE0525-Ab-2Anti-Rat TRABD2A monoclonal antibodyRat
GM-Tg-mg-SE0525-Ab-1/ GM-Tg-mg-SE0525-Ab-2Anti-Mouse TRABD2A monoclonal antibodyMouse
GM-Tg-cynog-SE0525-Ab-1/ GM-Tg-cynog-SE0525-Ab-2Anti-Cynomolgus/ Rhesus macaque TRABD2A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0525-Ab-1/ GM-Tg-felg-SE0525-Ab-2Anti-Feline TRABD2A monoclonal antibodyFeline
GM-Tg-cang-SE0525-Ab-1/ GM-Tg-cang-SE0525-Ab-2Anti-Canine TRABD2A monoclonal antibodyCanine
GM-Tg-bovg-SE0525-Ab-1/ GM-Tg-bovg-SE0525-Ab-2Anti-Bovine TRABD2A monoclonal antibodyBovine
GM-Tg-equg-SE0525-Ab-1/ GM-Tg-equg-SE0525-Ab-2Anti-Equine TRABD2A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0525-Ab-1/ GM-Tg-hg-SE0525-Ab-2; GM-Tg-rg-SE0525-Ab-1/ GM-Tg-rg-SE0525-Ab-2;
GM-Tg-mg-SE0525-Ab-1/ GM-Tg-mg-SE0525-Ab-2; GM-Tg-cynog-SE0525-Ab-1/ GM-Tg-cynog-SE0525-Ab-2;
GM-Tg-felg-SE0525-Ab-1/ GM-Tg-felg-SE0525-Ab-2; GM-Tg-cang-SE0525-Ab-1/ GM-Tg-cang-SE0525-Ab-2;
GM-Tg-bovg-SE0525-Ab-1/ GM-Tg-bovg-SE0525-Ab-2; GM-Tg-equg-SE0525-Ab-1/ GM-Tg-equg-SE0525-Ab-2
Products NameAnti-TRABD2A monoclonal antibody
Formatmab
Target NameTRABD2A
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TRABD2A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0525-Ag-1Recombinant multi-species TIKI1/ TRABD2A/ C2orf89 protein


    Target information

    Target IDGM-SE0525
    Target NameTRABD2A
    Gene ID129293,694038,483086,101089598,100067515
    Gene Symbol and SynonymsC17H2orf89,C2orf89,TIKI1,TRABD2A
    Uniprot AccessionQ86V40
    Uniprot Entry NameTIKI1_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000186854
    Target ClassificationN/A

    The target: TRABD2A, gene name: TRABD2A, also named as C2orf89, TIKI1. Enables Wnt-protein binding activity and metalloendopeptidase activity. Involved in negative regulation of Wnt signaling pathway and proteolysis. Is integral component of organelle membrane and integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.